Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas [PDF]
, 2018 Pilocytic astrocytomas represent the most common glioma subtype in young patients and account for 5.4% of all gliomas. They are characterized by alterations in the RAS–MAP kinase pathway, the most frequent being a tandem duplication on chromosome 7q34 ...
Appay, Romain +13 more
core +3 more sources
, 2018 Anorectal melanoma (AM) is a rare malignancy, characterized by aggressive behavior and a poor prognosis. AM is more frequent in female patients aged over 50 years.
Dario Didona +4 more
core +1 more source
BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review
Journal of Clinical Medicine, 2023 Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths globally. BRAF mutation is present in about 10% of CRC patients and is associated with a poor response to chemotherapy. These patients have a relatively poor prognosis. This review aims to assess the efficacy and safety of BRAF inhibitors in BRAF-mutated CRC patients.
Wajeeha Aiman +13 more
openaire +2 more sources
PLoS ONE, 2019 Screening for theranostic biomarkers is mandatory for the therapeutic management of cutaneous melanoma. BRAF and NRAS genes must be tested in routine clinical practice.
Audrey Vallée +5 more
doaj +1 more source
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. [PDF]
, 2016 Inhibitors of BRAFV600E kinase are currently under investigations in preclinical and clinical studies involving BRAFV600E glioma. Studies demonstrated clinical response to such individualized therapy in the majority of patients whereas in some patients ...
Berger, Mitchel S +12 more
core +1 more source
Acta Dermato-VenereologicaThe prognostic value of BRAF V600 mutation level on clinical outcomes in patients with BRAF V600-mutated metastatic melanoma treated with BRAF and MEK inhibitors remains uncertain.
Ariane Fizazi +5 more
doaj +1 more source
Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer
Chinese Journal of Lung Cancer, 2018 Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor ...
Xia LIU, Diansheng ZHONG
doaj +1 more source
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with TwoState-of-the-Art Techniques
Case Reports in Oncology, 2012 Background: Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BRAF mutation status has any predictive value for therapeutic approaches such as angiogenesis inhibition. Patients and Methods: We used 2 methods to analyze
Nicola L. Schoenewolf +8 more
doaj +1 more source
Rapid BRAF mutation tests in patients with advanced melanoma:Comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform [PDF]
, 2018 BRAF mutational testing has become a common practice in the diagnostic process of patients with advanced melanoma. Although time-consuming, DNA sequencing techniques are the current gold standard for mutational testing.
Ascierto +34 more
core +2 more sources
BRAFMutation in Metastatic Colorectal Cancer [PDF]
New England Journal of Medicine, 2009 To the Editor: We recently found that progression-free survival was shorter among patients with metastatic colorectal cancer treated with chemotherapy, bevacizumab, and cetuximab (CBC regimen) than among patients who received chemotherapy and bevacizumab alone (CB regimen) (Feb.
Tol, J., Nagtegaal, I.D., Punt, C.J.A.
openaire +4 more sources